Spots Global Cancer Trial Database for t cell receptor
Every month we try and update this database with for t cell receptor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | NCT03937791 | Squamous Lntrae... Neoplasms, Squa... Vulvar HSIL | E7 T Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | NCT02592577 | Non-Small Cell ... Carcinoma | Autologous Gene... | 18 Years - | Adaptimmune | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | NCT06358053 | Cervical Cancer Anal Cancer Head and Neck C... Other Solid Tum... | CRTE7A2-01 TCR-... | 18 Years - 65 Years | Corregene Biotechnology Co., Ltd | |
| E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | NCT04015336 | Papillomavirus ... Oropharyngeal N... | E7 T-Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer | NCT04044950 | Papillomavirus ... Oropharyngeal N... | E7 TCR | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer | NCT04476251 | Uterine Cervica... | E7 T-Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors | NCT03391791 | Solid and Hemat... | Genetically eng... | 18 Years - | Adaptimmune | |
| A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer | NCT04044950 | Papillomavirus ... Oropharyngeal N... | E7 TCR | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | NCT04015336 | Papillomavirus ... Oropharyngeal N... | E7 T-Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy | NCT05447234 | Gastric Cancer Gastroesophagea... | Tcrx T cell | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | NCT05194735 | Gynecologic Can... Colorectal Canc... Pancreatic Canc... Non-small Cell ... Cholangiocarcin... Ovarian Cancer Endometrial Can... Ovarian Carcino... Ovary Neoplasm Squamous Cell L... Adenocarcinoma ... Adenosquamous C... | Neoantigen spec... Aldesleukin (IL... | 18 Years - | Alaunos Therapeutics | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors | NCT03391791 | Solid and Hemat... | Genetically eng... | 18 Years - | Adaptimmune | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
